JP2015533797A - 高純度および優れた収率の正確に折り畳まれたエタネルセプト - Google Patents

高純度および優れた収率の正確に折り畳まれたエタネルセプト Download PDF

Info

Publication number
JP2015533797A
JP2015533797A JP2015531311A JP2015531311A JP2015533797A JP 2015533797 A JP2015533797 A JP 2015533797A JP 2015531311 A JP2015531311 A JP 2015531311A JP 2015531311 A JP2015531311 A JP 2015531311A JP 2015533797 A JP2015533797 A JP 2015533797A
Authority
JP
Japan
Prior art keywords
etanercept
protein
resin
mixed mode
folded
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015531311A
Other languages
English (en)
Japanese (ja)
Inventor
力 荒川
力 荒川
ファラー，ダグラス
Original Assignee
コヒラス・バイオサイエンシズ・インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50233493&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2015533797(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by コヒラス・バイオサイエンシズ・インコーポレイテッド filed Critical コヒラス・バイオサイエンシズ・インコーポレイテッド
Publication of JP2015533797A publication Critical patent/JP2015533797A/ja
Priority to JP2018192476A priority Critical patent/JP6913066B2/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/165—Extraction; Separation; Purification by chromatography mixed-mode chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
JP2015531311A 2012-09-11 2013-09-10 高純度および優れた収率の正確に折り畳まれたエタネルセプト Pending JP2015533797A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2018192476A JP6913066B2 (ja) 2012-09-11 2018-10-11 高純度および優れた収率の正確に折り畳まれたエタネルセプト

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261699552P 2012-09-11 2012-09-11
US61/699,552 2012-09-11
PCT/US2013/058994 WO2014043103A1 (en) 2012-09-11 2013-09-10 Correctly folded etanercept in high purity and excellent yield

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018192476A Division JP6913066B2 (ja) 2012-09-11 2018-10-11 高純度および優れた収率の正確に折り畳まれたエタネルセプト

Publications (1)

Publication Number Publication Date
JP2015533797A true JP2015533797A (ja) 2015-11-26

Family

ID=50233493

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2015531311A Pending JP2015533797A (ja) 2012-09-11 2013-09-10 高純度および優れた収率の正確に折り畳まれたエタネルセプト
JP2018192476A Expired - Fee Related JP6913066B2 (ja) 2012-09-11 2018-10-11 高純度および優れた収率の正確に折り畳まれたエタネルセプト
JP2021025939A Pending JP2021100929A (ja) 2012-09-11 2021-02-22 高純度および優れた収率の正確に折り畳まれたエタネルセプト

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2018192476A Expired - Fee Related JP6913066B2 (ja) 2012-09-11 2018-10-11 高純度および優れた収率の正確に折り畳まれたエタネルセプト
JP2021025939A Pending JP2021100929A (ja) 2012-09-11 2021-02-22 高純度および優れた収率の正確に折り畳まれたエタネルセプト

Country Status (33)

Country Link
US (6) US20140072560A1 (https=)
EP (1) EP2895188B1 (https=)
JP (3) JP2015533797A (https=)
KR (2) KR102133699B1 (https=)
CN (2) CN110051823A (https=)
AR (1) AR092532A1 (https=)
AU (2) AU2013315750B9 (https=)
BR (1) BR112015005161A2 (https=)
CA (1) CA2882551A1 (https=)
CL (1) CL2015000572A1 (https=)
CO (1) CO7400876A2 (https=)
CY (1) CY1120062T1 (https=)
DK (1) DK2895188T3 (https=)
DO (1) DOP2015000055A (https=)
EA (1) EA031324B1 (https=)
EC (1) ECSP15014138A (https=)
ES (1) ES2657377T3 (https=)
HR (1) HRP20180182T1 (https=)
HU (1) HUE036524T2 (https=)
IL (2) IL237311B (https=)
IN (1) IN2015KN00452A (https=)
LT (1) LT2895188T (https=)
MX (2) MX360044B (https=)
NO (1) NO2972131T3 (https=)
PE (2) PE20150996A1 (https=)
PL (1) PL2895188T3 (https=)
PT (1) PT2895188T (https=)
RS (1) RS57013B1 (https=)
SG (1) SG11201501460RA (https=)
SI (1) SI2895188T1 (https=)
SM (1) SMT201800163T1 (https=)
TW (2) TWI716649B (https=)
WO (1) WO2014043103A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020511516A (ja) * 2017-03-24 2020-04-16 カウンスィル オブ サイエンティフィック アンド インダストリアル リサーチＣｏｕｎｃｉｌ Ｏｆ Ｓｃｉｅｎｔｉｆｉｃ ＆ Ｉｎｄｕｓｔｒｉａｌ Ｒｅｓｅａｒｃｈ 組換え抗体断片の精製方法
JP2024539136A (ja) * 2021-10-19 2024-10-28 アルテオジェン・インコーポレイテッド ＩｇＧ Ｆｃドメインを有する融合タンパク質の精製方法

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0611901A2 (pt) 2005-06-14 2012-08-28 Amgen, Inc composição, liofilizado, kit, e, processo para preparar uma composição
BR112014009146A8 (pt) 2011-10-18 2017-06-20 Coherus Biosciences Inc formulações de etanercepte estabilizadas com aminoácidos
US10485869B2 (en) 2011-10-18 2019-11-26 Coherus Biosciences, Inc. Etanercept formulations stabilized with meglumine
SI2895188T1 (en) * 2012-09-11 2018-05-31 Coherus Biosciences, Inc. CORRECTED QUALITY ETHANERCEPT WITH HIGH QUALITY AND EXCELLENT EXPERIENCE
MX2016016318A (es) * 2014-06-13 2017-06-12 Lupin Atlantis Holdings Sa Proceso para la purificacion de la proteina de fusion.
ES2733298T3 (es) 2014-07-18 2019-11-28 Sandoz Ag Cuantificación de TNFR2:Fc plegado erróneamente
EP3241849A4 (en) 2014-12-31 2018-06-20 LG Chem, Ltd. Method for producing tnfr-fc fusion protein containing target content of impurities
EP3268042B1 (en) 2015-03-13 2024-11-27 Samsung Bioepis Co., Ltd. Anti-tnf-alpha polypeptide composition and use thereof
JP2018537458A (ja) * 2015-11-18 2018-12-20 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ 改善されたタンパク質分離のための逆ｐＨ塩勾配
BR112018009881A2 (pt) * 2015-11-18 2018-11-13 Merck Patent Gmbh separação de proteína aperfeiçoada em cromatografia de troca iônica
EP4549463A3 (en) * 2016-06-17 2025-07-30 F. Hoffmann-La Roche AG Purification of multispecific antibodies
PT3528787T (pt) 2016-10-21 2026-03-11 Amgen Inc Formulações farmacêuticas e métodos para produzir as mesmas
WO2018119142A1 (en) 2016-12-21 2018-06-28 Amgen Inc. Anti-tnf alpha antibody formulations
US11253569B2 (en) 2018-05-03 2022-02-22 Seattle Children's Hospital Methods of treating Kawasaki Disease
CN112876567A (zh) * 2019-11-29 2021-06-01 广东菲鹏制药股份有限公司 Fc融合蛋白及其纯化方法
AU2021262609A1 (en) 2020-05-01 2022-12-22 Kashiv Biosciences, Llc An improved process of purification of protein
WO2022195505A1 (en) * 2021-03-16 2022-09-22 Kashiv Biosciences, Llc Novel formulation of fusion protein
WO2022234412A1 (en) * 2021-05-03 2022-11-10 Lupin Limited A process for purification of fc-fusion proteins
EP4696709A1 (en) * 2024-12-06 2026-02-18 Qilu Pharmaceutical Co., Ltd. Variants of etanercept and related processes

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004017955A1 (en) * 2002-08-22 2004-03-04 Vasopharm Biotech Gmbh L-arginine containing pharmaceutical composition
JP2011514895A (ja) * 2008-02-29 2011-05-12 バイオジェン・アイデック・エムエイ・インコーポレイテッド 精製免疫グロブリン融合タンパク質およびその精製方法
WO2011141926A2 (en) * 2010-05-10 2011-11-17 Intas Biopharmaceuticals Limited Liquid formulation of polypeptides containing an fc domain of an immunoglobulin
US20120208986A1 (en) * 2009-10-20 2012-08-16 Wenger Marc D Use of mixed mode chromatography for the capture and purification of basic antibody products

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5395760A (en) 1989-09-05 1995-03-07 Immunex Corporation DNA encoding tumor necrosis factor-α and -β receptors
US5605690A (en) 1989-09-05 1997-02-25 Immunex Corporation Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor
EP0939121B2 (de) 1989-09-12 2007-12-26 AHP Manufacturing B.V. TFN-bindende Proteine
IT1240314B (it) 1989-09-28 1993-12-07 Immunobiology Research Institutes, Inc. Formulazioni acquose stabilizzate di piccoli peptidi.
DK0464533T3 (da) 1990-06-28 1999-04-26 Gen Hospital Corp Fusionsproteiner med immunglobulindele, deres fremstilling og anvendelse
AU670125B2 (en) 1992-09-15 1996-07-04 Immunex Corporation Method of treating tnf-dependent inflammation using tumor necrosis factor antagonists
EP0852951A1 (de) 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
US7294481B1 (en) 1999-01-05 2007-11-13 Immunex Corporation Method for producing recombinant proteins
US20010021380A1 (en) 1999-04-19 2001-09-13 Pluenneke John D. Soluble tumor necrosis factor receptor treatment of medical disorders
US20040220103A1 (en) 1999-04-19 2004-11-04 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical disorders
EP1171148A2 (en) 1999-04-19 2002-01-16 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical desorders
EP1261364A1 (en) 2000-02-10 2002-12-04 Wyeth Method of treating or inhibiting cellular injury or cell death
JP5485489B2 (ja) 2000-08-11 2014-05-07 中外製薬株式会社 抗体含有安定化製剤
IL157446A0 (en) 2001-02-23 2004-03-28 Immunex Corp Immunex Corp Increased recovery of active proteins
SI1478394T1 (sl) 2002-02-27 2008-12-31 Immunex Corp STABILIZIRAN TNFR-Fc SESTAVEK Z ARGININOM
US20040115263A1 (en) 2002-08-26 2004-06-17 Robertson David W. Use of bupropion for treating restless legs syndrome
JP4980048B2 (ja) 2003-02-28 2012-07-18 アレス トレーディング ソシエテ アノニム 腫瘍壊死因子結合タンパク質の液体製剤
US20060177444A1 (en) 2003-03-20 2006-08-10 Tatsuo Horizoe Concomitant drug as therapeutic agent for inflammatory bowel disease
BRPI0413197A (pt) 2003-08-01 2006-10-03 Amgen Inc cristal de eta wercept; método para fabricar um cristal de etanercept; composição; uso de um cristal de etanercept
WO2005037214A2 (en) 2003-10-14 2005-04-28 Intermune, Inc. Macrocyclic carboxylic acids and acylsulfonamides as inhibitors of hcv replication
KR101150050B1 (ko) * 2004-02-27 2012-07-05 지이 헬스케어 바이오-사이언시스 에이비 항체 정제 방법
WO2005082377A1 (ja) 2004-03-01 2005-09-09 Ajinomoto Co., Inc. 抗ヒトTNF-α抗体活性低下抑制剤
CA2557046A1 (en) 2004-03-05 2005-10-13 John Crowley Process for cell culturing by continuous perfusion and alternating tangential flow
US20070196364A1 (en) 2004-07-27 2007-08-23 Human Genome Sciences, Inc. Pharmaceutical Formulation and Process
TWI364458B (en) 2004-08-27 2012-05-21 Wyeth Res Ireland Ltd Production of tnfr-lg
CA2607697C (en) 2005-05-10 2015-01-06 Biogen Idec Ma Inc. Treating and evaluating inflammatory disorders
KR101367544B1 (ko) 2005-06-10 2014-02-26 추가이 세이야쿠 가부시키가이샤 메글루민을 함유하는 단백질 제제의 안정화제, 및 그의이용
US8476239B2 (en) 2005-12-20 2013-07-02 Bristol-Myers Squibb Company Stable protein formulations
BRPI0620316A2 (pt) 2005-12-21 2011-11-08 Wyeth Corp formulações de proteìnas com viscosidades reduzida e seus usos
CA2638811A1 (en) * 2006-02-03 2007-08-16 Medimmune, Llc Protein formulations
CA2646508A1 (en) 2006-03-17 2007-09-27 Biogen Idec Ma Inc. Stabilized polypeptide compositions
AU2007240732B2 (en) 2006-04-21 2013-07-04 Amgen, Inc. Buffering agents for biopharmaceutical formulations
TW200831129A (en) 2006-10-06 2008-08-01 Amgen Inc Stable formulations
EP2094247B1 (en) 2006-10-20 2022-06-29 Amgen Inc. Stable polypeptide formulations
ES2541546T3 (es) 2006-11-03 2015-07-21 Wyeth Llc Sustancias que inhiben la glucólisis en cultivo celular
CA2790018C (en) 2006-12-21 2015-02-03 Amgen Inc. Formulations
US7691980B2 (en) 2007-01-09 2010-04-06 Bio-Rad Laboratories, Inc. Enhanced capacity and purification of antibodies by mixed mode chromatography in the presence of aqueous-soluble nonionic organic polymers
AU2008223133A1 (en) 2007-03-02 2008-09-12 Wyeth Use of copper and glutamate in cell culture for production of polypeptides
EP2014760A1 (en) 2007-06-13 2009-01-14 CMC Biopharmaceuticals A/S A method for producing a biopolymer (e.g. polypeptide) in a continuous fermentation process
NZ595526A (en) 2007-06-14 2013-03-28 Biogen Idec Inc Pharmaceutical composition comprising a vla-4 binding antibody, a phosphate buffer and a surfactant
US8420081B2 (en) 2007-11-30 2013-04-16 Abbvie, Inc. Antibody formulations and methods of making same
US9238810B2 (en) * 2008-06-05 2016-01-19 Affibody Ab Polypeptide
WO2011015926A1 (en) * 2009-08-03 2011-02-10 Avesthagen Limited A process of fermentation, purification and production of recombinant soluble tumour necrosis factor alfa receptor (tnfr) - human igg fc fusion protein
EP2462157B1 (en) 2009-08-07 2020-06-17 EMD Millipore Corporation Methods for purifying a target protein from one or more impurities in a sample
HRP20200768T4 (hr) 2009-08-11 2025-03-28 F. Hoffmann - La Roche Ag Proizvodnja proteina u mediju za uzgoj stanica bez glutamina
WO2011079308A2 (en) 2009-12-23 2011-06-30 Emergent Product Development Seattle, Llc Compositions comprising tnf-alpha and il-6 antagonists and methods of use thereof
CA2797356C (en) 2010-04-26 2020-12-29 Novartis Ag Improved cell culture medium
EP2598167B1 (en) 2010-07-30 2015-04-01 Arecor Limited Stabilized aqueous antibody compositions
JP2013535981A (ja) 2010-08-20 2013-09-19 ワイス・エルエルシー 成長因子不含適合細胞の細胞培養
AU2011296702A1 (en) 2010-08-31 2013-03-21 Friesland Brands B.V. Culture medium for eukaryotic cells
EP2627425A4 (en) * 2010-10-11 2014-11-05 Abbvie Inc METHODS OF PURIFYING PROTEINS
EP2699265B1 (en) 2011-04-20 2019-10-16 Sandoz AG STABLE PHARMACEUTICAL LIQUID FORMULATIONS OF THE FUSION PROTEIN TNFR:Fc
UY34105A (es) 2011-06-03 2012-07-31 Lg Life Sciences Ltd Formulación líquida estable de etanercept
PT2837680T (pt) 2011-07-01 2020-04-17 Amgen Inc Cultura celular de mamífero
CN103930124B (zh) 2011-07-01 2021-05-11 生物基因Ma公司 无精氨酸的tnfr：fc-融合多肽组合物及使用方法
DK2729482T3 (en) * 2011-07-08 2018-05-07 Merck Sharp & Dohme PROCEDURE FOR CLEANING FC-FUSION PROTEIN
KR101454316B1 (ko) * 2011-08-17 2014-10-27 한화케미칼 주식회사 활성형 ＴＮＦＲ-Ｆｃ 융합 단백질을 제조하는 방법
BR112014009146A8 (pt) * 2011-10-18 2017-06-20 Coherus Biosciences Inc formulações de etanercepte estabilizadas com aminoácidos
US10485869B2 (en) * 2011-10-18 2019-11-26 Coherus Biosciences, Inc. Etanercept formulations stabilized with meglumine
HK1209343A1 (en) * 2012-07-09 2016-04-01 Coherus Biosciences, Inc. Etanercept formulations exhibiting marked reduction in sub-visible particles
SI2895188T1 (en) * 2012-09-11 2018-05-31 Coherus Biosciences, Inc. CORRECTED QUALITY ETHANERCEPT WITH HIGH QUALITY AND EXCELLENT EXPERIENCE
EP3879334B1 (en) * 2014-07-31 2023-11-29 Mtt Innovation Incorporated Numerical approaches for free-form lensing: area parameterization free-form lensing
US20160108634A1 (en) * 2014-10-16 2016-04-21 Ronald Uphold Pool Cover Hanger Device

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004017955A1 (en) * 2002-08-22 2004-03-04 Vasopharm Biotech Gmbh L-arginine containing pharmaceutical composition
JP2011514895A (ja) * 2008-02-29 2011-05-12 バイオジェン・アイデック・エムエイ・インコーポレイテッド 精製免疫グロブリン融合タンパク質およびその精製方法
US20120208986A1 (en) * 2009-10-20 2012-08-16 Wenger Marc D Use of mixed mode chromatography for the capture and purification of basic antibody products
WO2011141926A2 (en) * 2010-05-10 2011-11-17 Intas Biopharmaceuticals Limited Liquid formulation of polypeptides containing an fc domain of an immunoglobulin

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
BIOTECHNOL.BIOENG.,2008,100(4),P.605-18, JPN6015016951, ISSN: 0003596955 *
COEN MAAS, ET AL.: "A Role for Protein Misfolding in Immunogenicity of Biopharmaceuticals", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 282, JPN6017025414, 2007, pages 2229 - 2236, ISSN: 0003812817 *
J.BIOTECHNOL.,2001,87(2),P.143-59, JPN6015016949, ISSN: 0003596953 *
J.CHROMATOGR.A,2008,1177(2),P.265-71, JPN6015016948, ISSN: 0003596952 *
J.CHROMATOGR.A,2010,1217(2),P.225-34, JPN6015016953, ISSN: 0003596957 *
METHODS ENZYMOL.,2009,463,P.405-14, JPN6015016950, ISSN: 0003596954 *
PROTEIN EXPR.PURIF.,2010,70(2),P.191-5, JPN6015016952, ISSN: 0003596956 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020511516A (ja) * 2017-03-24 2020-04-16 カウンスィル オブ サイエンティフィック アンド インダストリアル リサーチＣｏｕｎｃｉｌ Ｏｆ Ｓｃｉｅｎｔｉｆｉｃ ＆ Ｉｎｄｕｓｔｒｉａｌ Ｒｅｓｅａｒｃｈ 組換え抗体断片の精製方法
JP7655610B2 (ja) 2017-03-24 2025-04-02 カウンスィル オブ サイエンティフィック アンド インダストリアル リサーチ 組換え抗体断片の精製方法
JP2024539136A (ja) * 2021-10-19 2024-10-28 アルテオジェン・インコーポレイテッド ＩｇＧ Ｆｃドメインを有する融合タンパク質の精製方法

Also Published As

Publication number Publication date
US20190300602A1 (en) 2019-10-03
US20190330325A1 (en) 2019-10-31
HUE036524T2 (hu) 2018-07-30
KR20150056601A (ko) 2015-05-26
US20190300601A1 (en) 2019-10-03
CY1120062T1 (el) 2018-12-12
CN110051823A (zh) 2019-07-26
EP2895188A4 (en) 2016-05-25
AU2013315750B9 (en) 2018-11-15
JP6913066B2 (ja) 2021-08-04
US10954294B2 (en) 2021-03-23
EA201590542A1 (ru) 2015-07-30
HRP20180182T1 (hr) 2018-04-20
US11001627B2 (en) 2021-05-11
AU2018247244A1 (en) 2018-11-01
JP2019038817A (ja) 2019-03-14
AU2018247244B2 (en) 2020-05-28
PE20150996A1 (es) 2015-08-01
MX2015003090A (es) 2015-07-14
US20140072560A1 (en) 2014-03-13
IL267452B (en) 2021-05-31
JP2021100929A (ja) 2021-07-08
TW201425331A (zh) 2014-07-01
PL2895188T3 (pl) 2018-06-29
TW201803593A (zh) 2018-02-01
ECSP15014138A (es) 2016-01-29
WO2014043103A1 (en) 2014-03-20
CN104902914B (zh) 2019-01-01
US10947306B2 (en) 2021-03-16
SI2895188T1 (en) 2018-05-31
CO7400876A2 (es) 2015-09-30
SMT201800163T1 (it) 2018-05-02
AR092532A1 (es) 2015-04-22
CN104902914A (zh) 2015-09-09
CA2882551A1 (en) 2014-03-20
AU2013315750A1 (en) 2015-03-05
MX2018012749A (es) 2020-11-12
US20190300600A1 (en) 2019-10-03
EP2895188A1 (en) 2015-07-22
EA031324B1 (ru) 2018-12-28
IL237311B (en) 2019-07-31
KR102133699B1 (ko) 2020-07-14
KR102250937B1 (ko) 2021-05-12
NO2972131T3 (https=) 2018-04-21
US10954295B2 (en) 2021-03-23
RS57013B1 (sr) 2018-05-31
US20180037642A1 (en) 2018-02-08
DK2895188T3 (en) 2018-02-26
IN2015KN00452A (https=) 2015-07-17
IL237311A0 (en) 2015-04-30
US10954293B2 (en) 2021-03-23
SG11201501460RA (en) 2015-04-29
PT2895188T (pt) 2018-02-08
KR20200085937A (ko) 2020-07-15
TWI609877B (zh) 2018-01-01
PE20200607A1 (es) 2020-03-10
EP2895188B1 (en) 2017-11-15
BR112015005161A2 (pt) 2017-07-04
LT2895188T (lt) 2018-04-10
AU2013315750B2 (en) 2018-07-12
ES2657377T3 (es) 2018-03-05
CL2015000572A1 (es) 2016-02-05
IL267452A (en) 2019-08-29
DOP2015000055A (es) 2015-04-30
TWI716649B (zh) 2021-01-21
MX360044B (es) 2018-10-19

Similar Documents

Publication Publication Date Title
US10954295B2 (en) Correctly folded etanercept in high purity and excellent yield
RU2736339C1 (ru) Слитый белок человеческого фактора свертывания IХ (FIX), способ его получения и применения
CN103998060B (zh) 使用糖与多元醇的结合物稳定的依那西普制剂
CA3182314A1 (en) An improved process of purification of protein
HK40009767A (zh) 高纯度和优异产量的正确折叠的依那西普
HK1200720B (en) Etanercept formulations stabilized with combinations of sugars and polyols

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150518

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160906

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170711

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20171005

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180110

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20180612

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20181012